Trials / Completed
CompletedNCT07052292
User Experience With DuraTouch® in Patients With Type 1 or Type 2 Diabetes
DuraTouch® - Post-Market Clinical Follow-up (PMCF) Study in a Real-world Setting
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 128 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study looks at overall impact of the use of DuraTouch® in terms of ease, convenience to use and satisfaction in participants with either type 1 or type 2 diabetes.The study will last for about 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | DuraTouch® | Participants will subcutaneously inject the insulin using DuraTouch®. |
Timeline
- Start date
- 2025-07-01
- Primary completion
- 2026-01-09
- Completion
- 2026-01-09
- First posted
- 2025-07-04
- Last updated
- 2026-04-09
Locations
11 sites across 1 country: Poland
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT07052292. Inclusion in this directory is not an endorsement.